Estimating the harms of nicotine-containing products using the MCDA approach
about
E-cigarettes: methodological and ideological issues and research prioritiesElectronic cigarette use and harm reversal: emerging evidence in the lungA Risk Assessment Matrix for Public Health Principles: The Case for E-CigarettesAre metals emitted from electronic cigarettes a reason for health concern? A risk-assessment analysis of currently available literatureShould academic journals publish e-cigarette research linked to tobacco companies?A Proposed Collaboration Against Big Tobacco: Common Ground Between the Vaping and Public Health Community in the United States.Patterns of Electronic Cigarette Use Among Adults in the United States.Overview of Electronic Nicotine Delivery Systems: A Systematic Review.How has the availability of snus influenced cigarette smoking in Norway?Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit.Electronic cigarettes have a potential for huge public health benefitDeficiencies in public understanding about tobacco harm reduction: results from a United States national surveyStudy of cardiovascular disease biomarkers among tobacco consumers. Part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey.Study of cardiovascular disease biomarkers among tobacco consumers, part 1: biomarkers of exposure.Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction.Protocol for a randomised pragmatic policy trial of nicotine products for quitting or long-term substitution in smokersGene expression profiles associated with cigarette smoking and moist snuff consumption.Physicians' Counseling of Adolescents Regarding E-Cigarette Use.Perceived relative harm of electronic cigarettes over time and impact on subsequent use. A survey with 1-year and 2-year follow-upsSwitching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 3. Biomarkers of biological effectSwitching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 1. Study design and methodology.Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 2. Biomarkers of exposure.Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes.E-Cigarette as a Harm Reduction Approach among Tobacco Smoking Khat Chewers: A Promising Bullet of Multiple GainsSocial Interactions as a Source of Information about E-Cigarettes: A Study of U.S. Adult Smokers.Long-term e-cigarette use and smoking cessation: a longitudinal study with US population.Everyday tactics in local moral worlds: E-cigarette practices in a working-class area of the UKViews and Preferences for Nicotine Products as an Alternative to Smoking: A Focus Group Study of People Living with Mental Disorders.Do never smokers make up an increasing share of snus users as cigarette smoking declines? Changes in smoking status among male snus users in Norway 2003-15.The Use of E-Cigarettes.Cross-sectional study examining the prevalence, correlates and sequencing of electronic cigarette and tobacco use among 11-16-year olds in schools in Wales.Electronic cigarette aerosol induces significantly less cytotoxicity than tobacco smokeDaily users compared to less frequent users find vape as or more satisfying and less dangerous than cigarettes, and are likelier to use non-cig-alike vaping productsPharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability.E-cigarettes, a safer alternative for teenagers? A UK focus group study of teenagers' views.Prevalence and Factors Associated with Smokeless Tobacco Use, 2014-2016.Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics.Computational Models Used to Assess US Tobacco Control Policies.Changing Perceptions of Harm of E-Cigarettes Among U.S. Adults, 2012-2015.Comparative in vitro toxicity profile of electronic and tobacco cigarettes, smokeless tobacco and nicotine replacement therapy products: e-liquids, extracts and collected aerosols
P2860
Q28082075-5C31990C-A81A-43B2-BE47-6D3C1D29242BQ28260197-57B62775-0CC3-4355-9381-1B5C194ECD05Q33615988-1D9E3DBF-4B6D-4BAA-BD2B-D0210B440CBBQ34476945-324B40F8-BEB2-44CD-B982-08D162F1521EQ34495956-280B4598-BC00-4156-BB5E-444CBE26ABEFQ34499623-C514DEE1-A516-4373-BAF5-13690931AE11Q34500158-4DCBB4C1-D607-43E1-9E97-4AB445AF3030Q34546578-A2B85D1C-3ABF-4817-A9AD-8AB32D60651BQ34578405-F0FC53D7-0A29-4B9F-9858-0A4AC116D1E2Q34584788-683A3A2D-3406-4AD1-844F-18C4C2832B7EQ34666977-FF0DF422-B971-44C6-A46E-42083455ABA9Q35806606-6127C926-FCF8-4B42-B4BF-D3C0FF969F43Q35834310-D1BC849B-39CA-469B-BE20-5C08F4CBC069Q35834322-28D59614-659F-4A57-BFC6-4C945C030A13Q36028493-6B24B213-C523-4881-BF65-9463512643ACQ36131179-A0AAE175-D286-4751-B10D-5C236E255FC0Q36279039-A7102E9A-78D4-4DC9-9BA1-C8E027B6C01BQ36315834-F86A97D2-A406-486A-9892-2D353B2950E9Q36390166-1C303B00-7371-4A45-AE7E-1692D86F43DBQ36482329-BAF35F64-566B-41C6-9290-A8F726E947BDQ36482338-7922376B-BDE1-4DF6-BA9C-5442777E58D8Q36482371-8590733E-E827-48F6-A983-3CB631BE5952Q36564246-96E1CF55-6D0D-4CC6-86AC-EFD1B67B2949Q36634004-EB965714-8A1B-4C8B-A436-E952E62622BCQ37202933-562268F9-4737-4B70-AE0E-D53DBFFE6349Q37398924-40F44793-FC20-4B3E-8DF7-435D53358B3AQ37423230-19E48812-54FD-44C7-A08F-73361F612AD2Q37456022-28E26C58-42B2-47EA-A538-76699045EAA5Q37595912-05380AAA-0EB4-45AF-A5E3-61C48891BA5EQ37610965-2B3F2636-E5A3-4649-A79C-339F6F98A604Q37627342-5ECAA218-4C71-4AFA-8415-6CA37B94E304Q37642791-94D8FCE3-0175-4EAB-B6F4-61873076E490Q37691520-FB28A463-2370-4879-ABA1-FEFB9E940289Q38375230-7A8329B3-489E-4416-8F90-BFE9818132E1Q38546302-5E03FE88-48B0-45F3-B9E5-649ABFE70FF8Q38651228-9A291547-A7B2-4F60-96D7-DD7ACF42B688Q38681340-E20FBE99-2688-411D-A3CF-30836CD3ACE1Q38740313-E99E8BA1-90F0-4267-A6F6-11FAB55638D9Q38877720-35AC61B2-660A-47E4-8863-55A140E3AC3AQ38943514-BF17215C-B3BC-4826-96A4-A72858B720D6
P2860
Estimating the harms of nicotine-containing products using the MCDA approach
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Estimating the harms of nicotine-containing products using the MCDA approach
@ast
Estimating the harms of nicotine-containing products using the MCDA approach
@en
Estimating the harms of nicotine-containing products using the MCDA approach
@nl
type
label
Estimating the harms of nicotine-containing products using the MCDA approach
@ast
Estimating the harms of nicotine-containing products using the MCDA approach
@en
Estimating the harms of nicotine-containing products using the MCDA approach
@nl
prefLabel
Estimating the harms of nicotine-containing products using the MCDA approach
@ast
Estimating the harms of nicotine-containing products using the MCDA approach
@en
Estimating the harms of nicotine-containing products using the MCDA approach
@nl
P2093
P2860
P3181
P356
P1476
Estimating the harms of nicotine-containing products using the MCDA approach
@en
P2093
Anders Milton
David Balfour
David Sweanor
H Valerie Curran
John Ramsey
Jonathan Foulds
Karl Fagerstrom
Kgosi Letlape
Lawrence D Phillips
Martin Dockrell
P2860
P304
P3181
P356
10.1159/000360220
P407
P50
P577
2014-01-01T00:00:00Z